IN BRIEF: GlaxoSmithKline seeks approval in US for use of Priorix

GlaxoSmithKline PLC - FTSE 100-listed pharmaceutical company - Submits biologics license ...

Alliance News 2 August, 2021 | 9:22PM
Email Form Facebook Twitter LinkedIn RSS

GlaxoSmithKline PLC - FTSE 100-listed pharmaceutical company - Submits biologics license application to US Food & Drug Administration for Priorix, and is seeking approval for use in immunisation against measles, mumps and rubella.

Priorix is currently licensed in more than 100 countries, including all countries in Europe, Canada, Australia and New Zealand.

"If approved, Priorix will increase the number of vaccine offerings from GSK against childhood

diseases in the US market and strengthen GSK's long-term commitment to prioritizing public health in the US," said Head of US Vaccines Judy Stewart.

Current stock price: 1,427.60 pence

Year-to-date change: up 6.4%

By Dayo Laniyan; dayolaniyan@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

Email Form Facebook Twitter LinkedIn RSS

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
GlaxoSmithKline PLC 1,388.00 GBX -1.84

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

© Copyright 2021 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Cookies       Modern Slavery Statement